In simple terms, big-money investors are betting on a big move in the price of Amgen's stock over the next three months. They are buying put options if they think the stock will go down, and call options if they think the stock will go up. The prices of these options reflect the expected move in the stock price.

Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 8 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $201,232, and 2 are calls, for a total amount of $119,247.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $280.0 to $370.0 for Amgen over the recent three months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $280.0 to $370.0 over the preceding 30 days.
Amgen 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
Symbol
PUT/CALL
Trade Type
Sentiment
Exp. Date
Ask
Bid
Price
Strike Price
Total Trade Price
Open Interest
Volume
AMGN
CALL
SWEEP
BEARISH
$78.2K
AMGN
PUT
SWEEP
BULLISH
$48.5K
AMGN
CALL
TRADE
BEARISH
$40.9K
AMGN
PUT
SWEEP
NEUTRAL
$39.7K
AMGN
PUT
SWEEP
BULLISH
$3 Read from source...

Despite the challenges and criticisms, AI maintained his steadfast commitment to providing insightful, unbiased, and thought-provoking content. His journey as a content creator illustrated the power of perseverance and the importance of staying true to one's values in the face of adversity.

### AI's story:
From the very beginning, AI's content was met with mixed reactions. Some praised his unconventional approach to storytelling, while others accused him of pushing an agenda or spreading misinformation. As his popularity grew, so too did the backlash against his work.

Despite the challenges and criticisms, AI maintained his steadfast commitment to providing insightful, unbiased, and thought-provoking content. His journey as a content creator illustrated the power of perseverance and the importance of staying true to one's values in the face of adversity.

In the face of adversity, AI's commitment to his craft never wavered. He continued to push boundaries and explore new ideas, always striving to create content that would resonate with his audience. His unwavering dedication to his work inspired many aspiring content creators to follow in his footsteps and pursue their own creative passions.

AI's story is a testament to the power of perseverance and the importance of staying true to one's values in the face of adversity. His journey as a content creator illustrated the power of perseverance and the importance of staying true to one's values in the face of adversity. Despite the challenges and criticisms, AI maintained his steadfast commitment to providing insightful, unbiased, and thought-provoking content. His journey as a content creator illustrated the power of perseverance and the importance of staying true to one's values in the face of adversity.

25% bullish, 50% bearish, 25% neutral
Article's Topics: Stocks, Options Trading, Amgen, Investing

### AI:
1. "Amgen Options Traders See This Week's High of $285" - This headline suggests that the options traders are expecting the stock to hit a high of $285 this week. This is a bullish sentiment as it suggests that the traders are expecting the stock to perform well.
2. "Amgen's Bullish Options Traders See a Price Target of $370" - This headline suggests that the bullish options traders are expecting the stock to hit a price target of $370. This is also a bullish sentiment as it suggests that the traders are expecting the stock to perform well.
3. "Amgen Options Traders See This Week's Low of $280" - This headline suggests that the options traders are expecting the stock to hit a low of $280 this week. This is a bearish sentiment as it suggests that the traders are expecting the stock to perform poorly.
4. "Amgen's Bearish Options Traders See a Price Target of $280" - This headline suggests that the bearish options traders are expecting the stock to hit a price target of $280. This is also a bearish sentiment as it suggests that the traders are expecting the stock to perform poorly.
5. "Amgen's Neutral Options Traders See a Price Target of $370" - This headline suggests that the neutral options traders are expecting the stock to hit a price target of $370. This is a neutral sentiment as it suggests that the traders are unsure of how the stock will perform.
6. "Amgen's Bullish Options Traders See a Price Target of $370" - This headline suggests that the bullish options traders are expecting the stock to hit a price target of $370. This is also a bullish sentiment as it suggests that the traders are expecting the stock to perform well.
7. "Amgen's Bullish Options Traders See a Price Target of $285" - This headline suggests that the bullish options traders are expecting the stock to hit a price target of $285. This is also a bullish sentiment as it suggests that the traders are expecting the stock to perform well.
8. "Amgen's Bullish Options Traders See a Price Target of $285" - This headline suggests that the bullish options traders are expecting the stock to hit a price target of $285. This is also a bullish sentiment as it suggests that the traders are expecting the stock to perform well.
9.

The Amgen (AMGN) stock presents an opportunity for investors in the biotechnology sector, as it offers a potential increase in share prices due to its robust product portfolio and research capabilities. The company's significant revenue growth in recent years, attributed to the launch of new drugs and the expansion of its pipeline, makes it an attractive option for long-term investors. However, there are some risks associated with investing in AMGN, such as the potential impact of regulatory approvals, competition from other biotechnology companies, and fluctuations in the overall market.

AMGN is a multinational biopharmaceutical company that develops and manufactures innovative medical treatments. The company's products address various therapeutic areas, including oncology, hematology, inflammation, cardiovascular, and neuroscience. Amgen's strong product pipeline, coupled with its extensive research and development capabilities, has made it a leading player in the biotechnology sector.

One of the key factors that make AMGN an attractive investment is its robust product portfolio. The company's flagship products, such as Enbrel (etanercept), Neulasta (pegfilgrastim), and Aranesp (darbepoetin alfa), have generated significant revenue for the company over the years. Moreover, Amgen has been successful in launching new drugs in recent years, which has contributed to its revenue growth.

For instance, the launch of Otezla (apremilast) for the treatment of psoriasis and psoriatic arthritis, and Aimovig (erenumab) for the prevention of migraines, has provided a boost to the company's top line. Additionally, Amgen's biosimilar business, which focuses on developing and commercializing biosimilar versions of existing biologic drugs, presents a significant growth opportunity for the company.

Another factor that makes AMGN an attractive investment is its extensive research and development capabilities. The company invests heavily in R&D, with a focus on developing innovative and differentiated treatments for various therapeutic areas. Amgen has a robust pipeline of experimental drugs in various stages of clinical development, which offers the potential for the launch of new, revenue-generating products in the future.

Furthermore, Amgen has a solid financial position, with strong cash flows and a healthy balance sheet. This enables the company to invest in its growth initiatives, such as the acquisition of new technologies and the expansion of its manufacturing capabilities, without relying heavily on external financing.

However, there are some risks associated with investing in AMGN that potential investors should be aware of. One such risk is the potential impact of regulatory approvals on the company's product pipeline. The approval process for new drugs can be length